Key facts
- This page summarizes Brian Schwartz's Form 4 filing for INFINITY PHARMACEUTICALS, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2022, 20:32.
Brian Schwartz - 16 Jun 2022 Form 4 Insider Report for INFINITY PHARMACEUTICALS, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 16 Jun 2022
- Net transaction value
- +$20,994
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2022, 20:32:29 UTC
- Prior SEC filing
- 16 Jun 2022
- Next SEC filing
- 03 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/Seth A. Tasker as attorney-in-fact for Brian Schwartz, M.D.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian Schwartz filed Form 4 for INFINITY PHARMACEUTICALS, INC. on 16 Jun 2022.
Change
- Previous filing in this sequence was filed on 16 Jun 2022.
- Current net transaction value: +$20,994.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INFI
transaction
Common Stock
Award
- Transaction value
- $20,994
- Shares
- +30,919
- Change %
- Price
- $0.6790*
- Shares after
- 30,919
- Date
- 16 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INFI
transaction
Derivative
Stock Option(right to buy)
Award
- Transaction value
- $0
- Shares
- +45,000
- Change %
- Price
- $0.000000
- Shares after
- 45,000
- Date
- 16 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,000
- Exercise price
- $0.6790
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of approximately 50% of such person's $42,000 annual retainer for service as a director.
Footnote F2
The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
SEC remarks
Exhibit 24 - Limited Power of Attorney